Custom Search


Thursday 01 December 2005

Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.

By: Kaczmarek I, Beiras-Fernandez A, Sadoni S, Bengel D, Deutsch MA, Meiser B, Reichart B.

Exp Clin Transplant 2005 Dec;3(2):381-4

Posttransplant lymphoproliferative disorders are severe complications that arise after solid organ transplantation, which are often related to Epstein- Barr virus. Reports are anecdotal, and a standardized therapy does not exist. We report a case of a 36-year-old man who developed posttransplant lymphoproliferative disorder of the oropharynx 1 year after receiving a heart transplant. A short review of the literature is presented, after which a new therapeutic approach that combines antiviral therapy, monoclonal antibodies, and a sirolimus-based maintenance immunosuppression regimen with reduced target trough levels of tacrolimus is introduced. The patient achieved complete remission and was free from recurrence 18 months after the therapy was initiated.

Use of this site is subject to the following terms of use